Last updated on July 2019

A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)


Brief description of study

This is a Phase 1/1b dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Clinical Study Identifier: NCT02500407

Find a site near you

Start Over

Tennessee Oncology

Nashville, TN United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

New York Uni Medical Center

New York, NY United States
  Connect »

The Alfred

Melbourne, Australia
  Connect »

Sansum Medical Clinic, Inc.

Santa Barbara, CA United States
  Connect »

Barts Cancer Institute

London, United Kingdom
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »